These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 15753394)
1. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer. Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394 [TBL] [Abstract][Full Text] [Related]
2. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137 [TBL] [Abstract][Full Text] [Related]
3. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776 [TBL] [Abstract][Full Text] [Related]
4. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Lee SJ; Kim HS; Yu R; Lee K; Gardner TA; Jung C; Jeng MH; Yeung F; Cheng L; Kao C Mol Ther; 2002 Sep; 6(3):415-21. PubMed ID: 12231179 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL. Jiménez JA; Li X; Zhang YP; Bae KH; Mohammadi Y; Pandya P; Kao C; Gardner TA Cancer Gene Ther; 2010 Mar; 17(3):180-91. PubMed ID: 19798123 [TBL] [Abstract][Full Text] [Related]
6. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements. Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Latham JP; Searle PF; Mautner V; James ND Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585 [TBL] [Abstract][Full Text] [Related]
9. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer. Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508 [TBL] [Abstract][Full Text] [Related]
11. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044 [TBL] [Abstract][Full Text] [Related]
12. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800 [TBL] [Abstract][Full Text] [Related]
13. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cheng WS; Dzojic H; Nilsson B; Tötterman TH; Essand M Cancer Gene Ther; 2006 Jan; 13(1):13-20. PubMed ID: 16052227 [TBL] [Abstract][Full Text] [Related]
14. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. Zhao W; Xu Y; Kong D; Liu R; Zhang Z; Jin C; Zhang Z; Xiu Y Urol Oncol; 2009; 27(5):539-47. PubMed ID: 18639471 [TBL] [Abstract][Full Text] [Related]
15. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281 [TBL] [Abstract][Full Text] [Related]
16. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model. Dzojic H; Cheng WS; Essand M Cancer Gene Ther; 2007 Mar; 14(3):233-40. PubMed ID: 17053814 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Li X; Zhang J; Gao H; Vieth E; Bae KH; Zhang YP; Lee SJ; Raikwar S; Gardner TA; Hutchins GD; VanderPutten D; Kao C; Jeng MH Mol Cancer Ther; 2005 Dec; 4(12):1850-9. PubMed ID: 16373700 [TBL] [Abstract][Full Text] [Related]
18. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053 [TBL] [Abstract][Full Text] [Related]
19. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Yu DC; Sakamoto GT; Henderson DR Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]